MXPA05011596A - Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato. - Google Patents

Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato.

Info

Publication number
MXPA05011596A
MXPA05011596A MXPA05011596A MXPA05011596A MXPA05011596A MX PA05011596 A MXPA05011596 A MX PA05011596A MX PA05011596 A MXPA05011596 A MX PA05011596A MX PA05011596 A MXPA05011596 A MX PA05011596A MX PA05011596 A MXPA05011596 A MX PA05011596A
Authority
MX
Mexico
Prior art keywords
sphingosine
amino
receptor modulator
phosphate receptor
propanol derivatives
Prior art date
Application number
MXPA05011596A
Other languages
English (en)
Inventor
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329500A external-priority patent/GB0329500D0/en
Priority claimed from GB0329505A external-priority patent/GB0329505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05011596A publication Critical patent/MXPA05011596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Los compuestos de formula (I), en donde R1, R2, R3, R4, R5, R6, R7, X, Y y n son como se define en la especificacion, procesos para su produccion, sus usos y composiciones farmaceuticas conteniendolos. (ver formula I).
MXPA05011596A 2003-04-30 2004-04-29 Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato. MXPA05011596A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0309944 2003-04-30
GB0329500A GB0329500D0 (en) 2003-12-19 2003-12-19 Organic compounds
GB0329505A GB0329505D0 (en) 2003-12-19 2003-12-19 Organic compounds
PCT/EP2004/004569 WO2004096752A1 (en) 2003-04-30 2004-04-29 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator

Publications (1)

Publication Number Publication Date
MXPA05011596A true MXPA05011596A (es) 2006-01-23

Family

ID=33424535

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011596A MXPA05011596A (es) 2003-04-30 2004-04-29 Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato.

Country Status (11)

Country Link
US (1) US7625950B2 (es)
EP (1) EP1622860B1 (es)
JP (1) JP4603531B2 (es)
CN (1) CN1777575B (es)
AT (1) ATE547395T1 (es)
AU (1) AU2004234066B2 (es)
BR (1) BRPI0410025A (es)
CA (1) CA2523582A1 (es)
ES (1) ES2383298T3 (es)
MX (1) MXPA05011596A (es)
WO (1) WO2004096752A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010949A2 (en) 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
AU2004234066B2 (en) * 2003-04-30 2008-02-21 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
CN102175786B (zh) 2003-08-28 2013-07-17 诺瓦提斯公司 氨基丙醇衍生物
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
CN101884781B (zh) * 2004-07-16 2012-07-18 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
RU2007109207A (ru) 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
RU2376285C2 (ru) 2004-10-12 2009-12-20 Киорин Фармасьютикал Ко., Лтд. Процесс получения гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенилэтил]-1,3-пропандиола] и его гидратов, а также промежуточные продукты их получения
EP1863463A1 (en) 2005-02-14 2007-12-12 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
JP4833998B2 (ja) 2005-12-15 2011-12-07 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
CN101378741A (zh) 2006-01-27 2009-03-04 弗吉尼亚大学专利基金会 治疗神经性疼痛的方法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007212193A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2007112322A2 (en) 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
NZ574012A (en) * 2006-08-08 2012-02-24 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
US8232319B2 (en) 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
NZ576893A (en) 2006-11-21 2012-01-12 Univ Virginia Patent Found Tetralin analogs having sphingosine 1-phosphate agonist activity
AU2007323540A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
JP5341754B2 (ja) * 2007-06-14 2013-11-13 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
RU2010112275A (ru) 2007-09-24 2011-11-10 Аллерган, Инк. (Us) Индольные соединения, содержащие арильные или гетероарильные группы, обладющие биологической активностью рецептора сфингозин-1-фосфата (с1ф)
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009137342A1 (en) 2008-05-08 2009-11-12 Allergan, Inc. Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido [ 3, 2, 1-i j ] quinoline compounds
US8143291B2 (en) 2008-05-09 2012-03-27 Allergan, Inc. Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity
EP2326621B1 (en) 2008-07-23 2016-06-08 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
CA2733671C (en) 2008-08-27 2018-01-02 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
BR112012009670A2 (pt) * 2009-10-23 2016-05-17 Allergan Inc compostos de cumarina como moduladores de receptor com utilidade terapêutica
MX2012006649A (es) * 2009-12-10 2012-06-25 Novartis Ag Derivados halogenados de fty720.
SG182610A1 (en) 2010-01-27 2012-08-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
CN102260178A (zh) * 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
MX2017008925A (es) 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171191T3 (es) * 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
GB2309868A (en) * 1996-01-30 1997-08-06 Sony Corp Radio receiver detects FCCH synchronising signal
DE69825056T2 (de) 1997-04-04 2005-08-25 Mitsubishi Pharma Corp. 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
AU6783698A (en) 1997-04-10 1998-10-30 Pharmacia & Upjohn Company Polyaromatic antiviral compositions
KR20030093279A (ko) * 2001-03-26 2003-12-06 노파르티스 아게 2-아미노-프로판올 유도체
JP2002316985A (ja) * 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CN1329372C (zh) * 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
US7612238B2 (en) * 2002-09-13 2009-11-03 Novartis Ag Amino-propanol derivatives
AU2004234066B2 (en) * 2003-04-30 2008-02-21 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator

Also Published As

Publication number Publication date
BRPI0410025A (pt) 2006-04-25
AU2004234066B2 (en) 2008-02-21
US20060211658A1 (en) 2006-09-21
AU2004234066A1 (en) 2004-11-11
ES2383298T3 (es) 2012-06-20
EP1622860A1 (en) 2006-02-08
JP4603531B2 (ja) 2010-12-22
CN1777575B (zh) 2010-05-12
JP2006524660A (ja) 2006-11-02
WO2004096752A1 (en) 2004-11-11
ATE547395T1 (de) 2012-03-15
CN1777575A (zh) 2006-05-24
CA2523582A1 (en) 2004-11-11
EP1622860B1 (en) 2012-02-29
US7625950B2 (en) 2009-12-01

Similar Documents

Publication Publication Date Title
MXPA05011596A (es) Derivados de amino-propanol como modulador de receptor de esfingosina-1-fosfato.
MXPA05011597A (es) Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
MXPA05013348A (es) Derivados de amino-propanol como moduladores del receptor de esfingosina-1-fosfato.
PL1753712T3 (pl) Pochodne aminopropanolu
TW200617009A (en) Organic compounds
SE0202133D0 (sv) Novel compounds
TW200801003A (en) Novel compounds
TW200635921A (en) Organic compounds
TW200626579A (en) Inhibitors of the interaction between MDM2 and p53
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200616995A (en) Novel compounds
HK1125358A1 (en) Substituted cyclohexylmethyl derivatives
PL1660449T3 (pl) Pochodne aminopropanolu
TW200740781A (en) Novel compounds
TW200738658A (en) Novel compounds
TW200505920A (en) Organic compounds
TW200833670A (en) Novel compounds 569
TW200635917A (en) Novel compounds
TW200635916A (en) Compounds
PL1831202T3 (pl) Pochodne pirolidyniowe jako receptory M3 muskarynowe
SE0303541D0 (sv) New compounds
MY144633A (en) New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them
TW200722418A (en) Novel compounds
SE0303090D0 (sv) Novel compounds
GEP20084502B (en) Piperazine compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general